Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Renaissance Technologies LLC lowered its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 51.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,800 shares of the company’s stock after selling 59,400 shares during the period. Renaissance Technologies LLC’s holdings in Structure Therapeutics were worth $2,690,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State of Wyoming purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $28,000. Sterling Capital Management LLC purchased a new position in Structure Therapeutics in the 1st quarter worth approximately $28,000. CWM LLC lifted its position in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. Assetmark Inc. lifted its position in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Structure Therapeutics in the fourth quarter valued at approximately $127,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $53.14 on Monday. The company’s fifty day simple moving average is $47.63 and its two-hundred day simple moving average is $53.95. The company has a market cap of $3.78 billion, a P/E ratio of -53.14 and a beta of -1.43. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.86 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GPCR shares. Citizens Jmp cut their target price on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. HC Wainwright dropped their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday. Finally, Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.